| |
Newsroom /
Health and Fitness
/
Healthcare
/
Influenza Vaccines - Pipeline Analysis and Market Forecasts to 2016
Influenza Vaccines - Pipeline Analysis and Market Forecasts to 2016
Influenza Vaccines Market is forecast to Show High Growth till 2016
Hyderabad,
AP,
India
(prbd.net)
22/01/2010
"Influenza Vaccines - Pipeline Analysis and Market Forecasts to 2016"
GlobalData estimates the global Influenza vaccines market to be worth $2.8 billion in 2009. It is forecast to grow at a CAGR of 12.7% to reach $6.4 billion by 2016. This high growth forecast is primarily attributed to the increase in patient population, a result of increasing world population, and the need to get vaccinated each year. This growth will be further supported by increased production capacities of companies to cater to the rising demand. The strong product pipeline will complement the existing products by providing effective options to the people.
GlobalData found that the products currently in the market are highly efficacious in providing protection against the disease with minimum side-effects. All the marketed products provide high seroprotection rates and seroconversion rates against the disease. The key products like Fluzone, Fluvirin, Fluarix, FluLaval etc. are able to satisfy the demands of the influenza vaccines market. The unmet need arises from the fact that vaccination against one strain of virus may not provide protection against other strains of the influenza virus. More importantly, the virus strains tend to change every year, and hence people would have to get vaccinated for protection against the new virus each year.
The Influenza vaccines market has very low unmet needs as the market is very well served by the current product options. This leaves little scope for new entrants to capture value from under-served segments. The new products have to aim at gaining market share by providing unique offerings and targeting niche segments. The likely under-served segments are elderly population and people allergic to egg based vaccines. The current pipeline, however, is strong enough to cater to this unmet need.
GlobalData analyzed that the product pipeline for Influenza vaccines is strong with 84 molecules in various phases of clinical development. There are seven molecules in Phase III, 18 in Phase II and 24 molecules undergoing Phase I clinical trials. These vaccines are equally safe and efficacious than the currently marketed ones with novel development procedure or routes of administration. They target the small unmet need that exists in the market. They will compete with the well established marketed vaccines and are likely to redefine the competitive landscape of the market.
GlobalData, the industry analysis specialist’s new report, “Influenza Vaccines – Pipeline Analysis and Market Forecasts to 2015”, is an essential source of information and analysis on the global influenza vaccines market. Key trends shaping and driving the global influenza vaccines market are clearly identified in the report. The report provides an insight into the prevalent competitive landscape and the emerging players expected to bring about a significant shift in the market positioning of the existing market leaders. Most importantly, valuable insights into the pipeline products within the global Influenza vaccines sector are also provided.
Or Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|